

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ : C07D 471/04, 239/42, A61K 31/505, 31/435	A1	(11) International Publication Number: WO 99/61442 (43) International Publication Date: 2 December 1999 (02.12.99)
--	-----------	---

(21) International Application Number: **PCT/US99/11463**
(22) International Filing Date: **24 May 1999 (24.05.99)**
(30) Priority Data:
60/086,723 **26 May 1998 (26.05.98)** **US**
(71) Applicant (for all designated States except US): **MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).**
(72) Inventors; and
(75) Inventors/Applicants (for US only): **SANDERSON, Philip, E. [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). NAYLOR-OLSEN, Adel, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).**
(74) Common Representative: **MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).**


(81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.


(54) Title: **IMIDAZOPYRIDINE THROMBIN INHIBITORS**




(I)



(II)




(III)



(IV)



(V)



(VI)

(57) Abstract

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having structure (I) or (II), wherein Y¹ and Y² are independently selected from the group consisting of hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₃₋₇ cycloalkyl, halogen, and trifluoromethyl; and A is (III), (IV), (V), or (VI).

Ref. #47
3204/2 (PHA 4162.3)
M. South et al.
USSN: 09/717,051

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION
IMIDAZOPYRIDINE THROMBIN INHIBITORS

BACKGROUND OF THE INVENTION

5 Thrombin is a serine protease present in blood plasma in the form of a precursor, prothrombin. Thrombin plays a central role in the mechanism of blood coagulation by converting the solution plasma protein, fibrinogen, into insoluble fibrin.

Edwards *et al.*, *J. Amer. Chem. Soc.*, (1992) vol. 114, pp. 1854-63, describes peptidyl α -ketobenzoxazoles which are reversible inhibitors of the serine proteases human leukocyte elastase and porcine pancreatic elastase.

European Publication 363 284 describes analogs of peptidase substrates in which the nitrogen atom of the scissile amide group of the substrate peptide has been replaced by hydrogen or a substituted carbonyl moiety.

Australian Publication 86245677 also describes peptidase inhibitors having an activated electrophilic ketone moiety such as fluoromethylene ketone or α -keto carboxyl derivatives.

20 R. J. Brown *et al.*, *J. Med. Chem.*, Vol. 37, pages 1259-1261 (1994) describes orally active, non-peptidic inhibitors of human leukocyte elastase which contain trifluoromethylketone and pyridinone moieties.


H. Mack *et al.*, *J. Enzyme Inhibition*, Vol. 9, pages 73-86 (1995) describes rigid amidino-phenylalanine thrombin inhibitors which contain a pyridinone moiety as a central core structure.

25

SUMMARY OF THE INVENTION

The invention includes compounds for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. These compounds may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents. The compounds can be added to blood, blood

30





products, or mammalian organs in order to effect the desired inhibitions.

The invention also includes a compound for preventing or treating unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels, in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. These compounds may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.

The invention also includes a method for reducing the thrombogenicity of a surface in a mammal by attaching to the surface, either covalently or noncovalently, a compound of the invention.

DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

Compounds of the invention, useful as thrombin inhibitors and having therapeutic value in for example, preventing coronary artery disease, have the following structure (formula I or II):







or a pharmaceutically acceptable salt thereof, wherein

Y¹ and Y² are independently selected from the group consisting of

5 hydrogen,
 C₁₋₄ alkyl,
 C₁₋₄ alkoxy,
 C₃₋₇ cycloalkyl,
 halogen, and
 trifluoromethyl;

A is



W is -


- 5 hydrogen,
 R¹,
 R¹OCO,
 R¹CO,
 R¹SO₂,
 10 R¹(CH₂)_nNHCO, or
 (R¹)₂CH(CH₂)_nNHCO,

wherein n is 0-4;

R¹ is

- 5 R²,
 R²(CH₂)_mC(R¹²)₂, where m is 0-3, and each R¹² can be the same
 or different,
 (R²)(OR²)CH(CH₂)_p, where p is 1-4,

R² (CH₂)_m, where m is 0-3,



- 10 R²C(R¹²)₂(CH₂)_m, wherein m is 0-3, and each R¹² can be the
 same or different, wherein (R¹²)₂ can also form a ring with
 C represented by C3-7 cycloalkyl,
 R²CH₂C(R¹²)₂(CH₂)_q, wherein q is 0-2, and each R¹² can be the
 same or different, wherein (R¹²)₂ can also form a ring with
15 C represented by C3-7 cycloalkyl,
 (R²)₂CH(CH₂)_r, where r is 0-4 and each R² can be the same or
 different, and wherein (R²)₂ can also form a ring with CH
 represented by C3-7 cycloalkyl, C7-12 bicyclic alkyl, C10-16
 tricyclic alkyl, or a 5- to 7- membered mono- or bicyclic
20 heterocyclic ring which can be saturated or unsaturated,
 and which contains from one to three heteroatoms selected
 from the group consisting of N, O and S,
 R²O(CH₂)_p, wherein p is 1-4,
 R²CF₂C(R¹²)₂,
25 (R²CH₂)(R²CH₂)CH, or
 R²(COOR⁶)(CH₂)_r, where r is 1-4;

R² and R⁵ are independently




- 30 phenyl, unsubstituted or substituted with one or more of C₁₋₄
 alkyl, C₁₋₄ alkoxy, halogen, hydroxy, COOH, CONH₂,
 CH₂OH, CO₂R⁷, where R⁷ is C₁₋₄ alkyl, or SO₂NH₂,
 naphthyl,

- biphenyl,
a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
heterocyclic ring or non-heterocyclic ring which can be
saturated or unsaturated, wherein the heterocyclic ring
contains from one to four heteroatoms selected from the group
consisting of N, O and S, and wherein the heterocyclic or non-
heterocyclic ring is unsubstituted or substituted with halogen or
hydroxy,
C₁₋₇ alkyl, unsubstituted or substituted with one or more of
hydroxy,
COOH,
amino,
aryl,
C₃₋₇ cycloalkyl,
CF₃,
N(CH₃)₂,
-C₁₋₃alkylaryl,
heteroaryl, or
heterocycloalkyl,
CF₃
C₃₋₇ cycloalkyl, unsubstituted or substituted with aryl,
C₇₋₁₂ bicyclic alkyl, or
C₁₀₋₁₆ tricyclic alkyl;
- 25 R³, R⁴ and R⁶ are independently selected from the group consisting of
hydrogen,
C₁₋₄ alkyl,
C₃₋₇ cycloalkyl, or
trifluoromethyl;
- 30 X is
hydrogen, or
halogen;
- 35 Z is CH₂, S, or SO₂;

R¹² is




- hydrogen,
phenyl, unsubstituted or substituted with one or more of C₁₋₄
5 alkyl, C₁₋₄ alkoxy, halogen, hydroxy, COOH, CONH₂,
naphthyl,
biphenyl,
a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
heterocyclic ring which can be saturated or unsaturated, and
10 which contains from one to four heteroatoms selected from the
group consisting of N, O and S,
C₁₋₄ alkyl, unsubstituted or substituted with one or more of
hydroxy,
COOH,
15 amino,
aryl,
heteroaryl, or
heterocycloalkyl,
CF₃
20 C₃₋₇ cycloalkyl,
C₇₋₁₂ bicyclic alkyl, or
C₁₀₋₁₆ tricyclic alkyl.

A class of compounds of the invention, or a
pharmaceutically acceptable salt thereof, includes those wherein A is
25




- A subclass of compounds of this class, or a pharmaceutically acceptable salt thereof, includes those wherein Y^1 and Y^2 are hydrogen or C_{1-4} alkyl; W is hydrogen or R^1 ; R^1 is R^2 or R^2SO_2 ;
- 5 R^2 and R^5 are independently selected from the group consisting of C_{1-7} alkyl unsubstituted or substituted with aryl, C_{3-7} cycloalkyl, or heteroaryl; R^3 and R^4 are independently selected from the group consisting of hydrogen and C_{1-4} alkyl; and Z is SO_2 .

- In a group of compounds of this subclass, or a pharmaceutically acceptable salt thereof, Y^1 and Y^2 are hydrogen or methyl; W is hydrogen or
- 10



R^5 is



5




R^3 and R^4 are independently selected from the group consisting of hydrogen and methyl.

Examples of this group are listed below in Table 1.

10 Inhibitory activity of compounds of the invention is represented by "*", indicating K_i greater than or equal to 20 nM, or "**", indicating K_i less than 20 nM. Values are as determined according to the in vitro assay described later in the specification.

Table 1

	*
	**
	*
	*
	*
	**
	**

Table 1 (continued)

The compounds of the present invention, may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. The compounds of the present invention may also have polymorphic crystalline forms, with all polymorphic crystalline forms being included in the present invention.

When any variable occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein except where noted, "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl); "alkoxy" represents a linear or branched alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "Halo", as used herein, means fluoro, chloro,

bromo and iodo; and "counterion" is used to represent a small, single negatively-charged species, such as chloride, bromide, hydroxide, acetate, trifluoroacetate, perchlorate, nitrate, benzoate, maleate, sulfate, tartrate, hemitartrate, benzene sulfonate, and the like.

5 The term "C3-7cycloalkyl" is intended to include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and the like.

 The term "C7-12 bicyclic alkyl" is intended to include bicyclo[2.2.1]heptyl (norbornyl), bicyclo[2.2.2]octyl, 1,1,3-trimethyl-
10 bicyclo[2.2.1]heptyl (bornyl), and the like.

 The term "aryl" as used herein except where noted, represents a stable 6- to 10-membered mono- or bicyclic ring system. The aryl ring can be unsubstituted or substituted with one or more of C1-4 lower alkyl; hydroxy; alkoxy; halogen; amino. Examples of "aryl"
15 groups include phenyl and naphthyl.

 The term "heterocycle" or "heterocyclic ring", as used herein except where noted, represents a stable 5- to 7-membered mono- or bicyclic or stable 9- to 10-membered bicyclic heterocyclic ring system any ring of which may be saturated or unsaturated, and which consists
20 of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene
25 ring. Bicyclic unsaturated ring systems include bicyclic ring systems which may be partially unsaturated or fully unsaturated. Partially unsaturated bicyclic ring systems include, for example, cyclopentenopyridinyl, benzodioxan, methylenedioxyphenyl groups. Especially useful are rings containing one oxygen or sulfur, one to four
30 nitrogen atoms, or one oxygen or sulfur combined with one or two nitrogen atoms. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic groups include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-
35 oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl,

pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl,
pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl,
isoxazolidinyl, morpholinyl, thiazolyl, thiophenyl, oxazolyl,
thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl,
5 quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl,
benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl,
tetrazole, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl
sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl. Morpholino is the
same as morpholinyl. Unsaturated heterocyclic rings may also be
10 referred to hereinafter as "heteroaryl" rings.

The pharmaceutically-acceptable salts of the compounds of
Formula I (in the form of water- or oil-soluble or dispersible products)
include the conventional non-toxic salts such as those derived from
inorganic acids, e.g. hydrochloric, hydrobromic, sulfuric, sulfamic,
15 phosphoric, nitric and the like, or the quaternary ammonium salts
which are formed, e.g., from inorganic or organic acids or bases.
Examples of acid addition salts include acetate, adipate, alginate,
aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate,
camphorate, camphorsulfonate, cyclopentanepropionate, digluconate,
20 dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate,
glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride,
hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate,
pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate,
25 propionate, succinate, sulfate, tartrate, thiocyanate, tosylate, and
undecanoate. Base salts include ammonium salts, alkali metal salts
such as sodium and potassium salts, alkaline earth metal salts such as
calcium and magnesium salts, salts with organic bases such as
dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino
30 acids such as arginine, lysine, and so forth. Also, the basic nitrogen-
containing groups may be quaternized with such agents as lower alkyl
halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and
iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl
sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl

chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.

5 Some abbreviations that may appear in this application are as follows.

ABBREVIATIONS

Designation

BOC (Boc)

CBZ (Cbz)

TBS (TBDMS)

Protecting Group

t-butyloxycarbonyl

benzyloxycarbonyl(carbobenzoxy)

t-butyl-dimethylsilyl

Activating Group

HBT(HOBT or HOBt)

1-hydroxybenzotriazole hydrate

Designation

BOP reagent

BOP-Cl

EDC

Coupling Reagent

benzotriazol-1-yloxytris-

(dimethylamino)phosphonium

hexafluorophosphate

bis(2-oxo-3-oxazolidinyl)phosphinic chloride

1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride

Other

(BOC)₂O (BOC₂O)

n-Bu₄N⁺F⁻

nBuLi (n-Buli)

DMF

Et₃N (TEA)

EtOAc

TFA

DMAP

DME

NMM

DPPA

di-t-butyl dicarbonate

tetrabutyl ammonium fluoride

n-butyllithium

dimethylformamide

triethylamine

ethyl acetate

trifluoroacetic acid

dimethylaminopyridine

dimethoxyethane

N-methylmorpholine

diphenylphosphoryl azide

THF	tetrahydrofuran
DIPEA	diisopropylethylamine

	<u>Amino Acid</u>
Ile	Isoleucine
Phe	Phenylalanine
Pro	Proline
Ala	Alanine
Val	Valine

IN VITRO ASSAY FOR DETERMINING PROTEINASE INHIBITION

Assays of human α -thrombin and human trypsin were
 5 performed by the methods substantially as described in *Thrombosis Research*, Issue No. 70, page 173 (1993) by S.D. Lewis *et al.*

The assays were carried out at 25°C in 0.05 M TRIS buffer
 pH 7.4, 0.15 M NaCl, 0.1% PEG. Trypsin assays also contained 1 mM
 CaCl₂. In assays wherein rates of hydrolysis of a *p*-nitroanilide (pna)
 10 substrate were determined, a Thermomax 96-well plate reader was used
 was used to measure (at 405 nm) the time dependent appearance of *p*-
 nitroaniline. sar-PR-pna was used to assay human α -thrombin
 (K_m=125 μ M) and bovine trypsin (K_m=125 μ M). *p*-Nitroanilide substrate
 concentration was determined from measurements of absorbance at 342
 15 nm using an extinction coefficient of 8270 cm⁻¹M⁻¹.

In certain studies with potent inhibitors (K_i < 10 nM) where
 the degree of inhibition of thrombin was high, a more sensitive activity
 assay was employed. In this assay the rate of thrombin catalyzed
 hydrolysis of the fluorogenic substrate Z-GPR-afc (K_m=27 μ M) was
 20 determined from the increase in fluorescence at 500 nm (excitation at
 400 nm) associated with production of 7-amino-4-trifluoromethyl
 coumarin. Concentrations of stock solutions of Z-GPR-afc were
 determined from measurements of absorbance at 380 nm of the 7-amino-
 4-trifluoromethyl coumarin produced upon complete hydrolysis of an
 25 aliquot of the stock solution by thrombin.

Activity assays were performed by diluting a stock solution of substrate at least tenfold to a final concentration $\leq 0.1 K_M$ into a solution containing enzyme or enzyme equilibrated with inhibitor. Times required to achieve equilibration between enzyme and inhibitor were determined in control experiments. Initial velocities of product formation in the absence (V_0) or presence of inhibitor (V_i) were measured. Assuming competitive inhibition, and that unity is negligible compared $K_M/[S]$, $[I]/e$, and $[I]/e$ (where $[S]$, $[I]$, and e respectively represent the total concentrations, of substrate, inhibitor and enzyme), the equilibrium constant (K_i) for dissociation of the inhibitor from the enzyme can be obtained from the dependence of V_0/V_i on $[I]$ shown in equation 1.

$$V_0/V_i = 1 + [I]/K_i \quad (1)$$

The activities shown by this assay indicate that the compounds of the invention are therapeutically useful for treating various conditions in patients suffering from unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, and reocclusion or restenosis of recanalized vessels. The compounds of the invention are selective compounds, as evidenced by their inhibitory activity against human trypsin (represented by K_i), which is at least 1000 nM.

Thrombin Inhibitors - Therapeutic Uses- Method of Using

Anticoagulant therapy is indicated for the treatment and prevention of a variety of thrombotic conditions, particularly coronary artery and cerebrovascular disease. Those experienced in this field are readily aware of the circumstances requiring anticoagulant therapy. The term "patient" used herein is taken to mean mammals such as primates, including humans, sheep, horses, cattle, pigs, dogs, cats, rats, and mice.

Thrombin inhibition is useful not only in the anticoagulant therapy of individuals having thrombotic conditions, but is useful

whenever inhibition of blood coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus, the thrombin inhibitors can be added to or contacted with any medium containing or suspected of containing thrombin and in which it is desired that blood coagulation be inhibited, e.g., when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems.

Compounds of the invention are useful for treating or preventing venous thromboembolism (e.g. obstruction or occlusion of a vein by a detached thrombus; obstruction or occlusion of a lung artery by a detached thrombus), cardiogenic thromboembolism (e.g. obstruction or occlusion of the heart by a detached thrombus), arterial thrombosis (e.g. formation of a thrombus within an artery that may cause infarction of tissue supplied by the artery), atherosclerosis (e.g. arteriosclerosis characterized by irregularly distributed lipid deposits) in mammals, and for lowering the propensity of devices that come into contact with blood to clot blood.

Examples of venous thromboembolism which may be treated or prevented with compounds of the invention include obstruction of a vein, obstruction of a lung artery (pulmonary embolism), deep vein thrombosis, thrombosis associated with cancer and cancer chemotherapy, thrombosis inherited with thrombophilic diseases such as Protein C deficiency, Protein S deficiency, antithrombin III deficiency, and Factor V Leiden, and thrombosis resulting from acquired thrombophilic disorders such as systemic lupus erythematosus (inflammatory connective tissue disease). Also with regard to venous thromboembolism, compounds of the invention are useful for maintaining patency of indwelling catheters.

Examples of cardiogenic thromboembolism which may be treated or prevented with compounds of the invention include thromboembolic stroke (detached thrombus causing neurological affliction related to impaired cerebral blood supply), cardiogenic thromboembolism associated with atrial fibrillation (rapid, irregular twitching of upper heart chamber muscular fibrils), cardiogenic

thromboembolism associated with prosthetic heart valves such as mechanical heart valves, and cardiogenic thromboembolism associated with heart disease.

Examples of arterial thrombosis include unstable angina
5 (severe constrictive pain in chest of coronary origin), myocardial infarction (heart muscle cell death resulting from insufficient blood supply), ischemic heart disease (local anemia due to obstruction (such as by arterial narrowing) of blood supply), reocclusion during or after percutaneous transluminal coronary angioplasty, restenosis after
10 percutaneous transluminal coronary angioplasty, occlusion of coronary artery bypass grafts, and occlusive cerebrovascular disease. Also with regard to arterial thrombosis, compounds of the invention are useful for maintaining patency in arteriovenous cannulas.

Examples of atherosclerosis include arteriosclerosis.

15 Examples of devices that come into contact with blood include vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems

The thrombin inhibitors of the invention can be administered in such oral forms as tablets, capsules (each of which
20 includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical
25 arts. An effective but non-toxic amount of the compound desired can be employed as an anti-aggregation agent. For treating ocular build up of fibrin, the compounds may be administered intraocularly or topically as well as orally or parenterally.

The thrombin inhibitors can be administered in the form of
30 a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient. The active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants. Implants may employ inert materials such as biodegradable

polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers manufactured by the Dow-Corning Corporation.

The thrombin inhibitors can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The thrombin inhibitors may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The thrombin inhibitors may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the thrombin inhibitors may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.

The dosage regimen utilizing the thrombin inhibitors is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

Oral dosages of the thrombin inhibitors, when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 30 mg/kg/day, preferably 0.025-7.5 mg/kg/day, more preferably 0.1-2.5 mg/kg/day, and most preferably 0.1-0.5 mg/kg/day (unless specified otherwise, amounts of active ingredients are on free base basis). For example, an 80 kg patient would receive between about 0.8 mg/day and 2.4 g/day, preferably 2-600 mg/day,

more preferably 8-200 mg/day, and most preferably 8-40 mg/kg/day. A suitably prepared medicament for once a day administration would thus contain between 0.8 mg and 2.4 g, preferably between 2 mg and 600 mg, more preferably between 8 mg and 200 mg, and most preferably 8 mg and 40 mg, e.g., 8 mg, 10 mg, 20 mg and 40 mg. Advantageously, the thrombin inhibitors may be administered in divided doses of two, three, or four times daily. For administration twice a day, a suitably prepared medicament would contain between 0.4 mg and 4 g, preferably between 1 mg and 300 mg, more preferably between 4 mg and 100 mg, and most preferably 4 mg and 20 mg, e.g., 4 mg, 5 mg, 10 mg and 20 mg.

Intravenously, the patient would receive the active ingredient in quantities sufficient to deliver between 0.025-7.5 mg/kg/day, preferably 0.1-2.5 mg/kg/day, and more preferably 0.1-0.5 mg/kg/day. Such quantities may be administered in a number of suitable ways, e.g. large volumes of low concentrations of active ingredient during one extended period of time or several times a day, low volumes of high concentrations of active ingredient during a short period of time, e.g. once a day. Typically, a conventional intravenous formulation may be prepared which contains a concentration of active ingredient of between about 0.01-1.0 mg/ml, e.g. 0.1 mg/ml, 0.3 mg/ml, and 0.6 mg/ml, and administered in amounts per day of between 0.01 ml/kg patient weight and 10.0 ml/kg patient weight, e.g. 0.1 ml/kg, 0.2 ml/kg, 0.5 ml/kg. In one example, an 80 kg patient, receiving 8 ml twice a day of an intravenous formulation having a concentration of active ingredient of 0.5 mg/ml, receives 8 mg of active ingredient per day. Glucuronic acid, L-lactic acid, acetic acid, citric acid or any pharmaceutically acceptable acid/conjugate base with reasonable buffering capacity in the pH range acceptable for intravenous administration may be used as buffers. Consideration should be given to the solubility of the drug in choosing an appropriate buffer and pH of a formulation, depending on solubility of the drug to be administered, is readily made by a person having ordinary skill in the art.

The compounds can also be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to

those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regime.

The thrombin inhibitors are typically administered as active ingredients in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixers, syrups and the like, and consistent with convention pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn-sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.

Typical uncoated tablet cores suitable for administration of thrombin inhibitors are comprised of, but not limited to, the following amounts of standard ingredients:

<u>Excipient</u>	<u>General</u>	<u>Preferred</u>	<u>Most Preferred</u>
	<u>Range (%)</u>	<u>Range (%)</u>	<u>Range (%)</u>

<u>mannitol</u>	<u>10-90</u>	<u>25-75</u>	<u>30-60</u>
<u>microcrystalline</u>	<u>10-90</u>	<u>25-75</u>	<u>30-60</u>
<u>cellulose</u>			
<u>magnesium</u>	<u>0.1-5.0</u>	<u>0.1-2.5</u>	<u>0.5-1.5</u>
<u>stearate</u>			

Mannitol, microcrystalline cellulose and magnesium stearate may be substituted with alternative pharmaceutically acceptable excipients.

The thrombin inhibitors can also be co-administered with
5 suitable anti-platelet agents, including, but not limited to, fibrinogen receptor antagonists (e.g. to treat or prevent unstable angina or to prevent reocclusion after angioplasty and restenosis), anticoagulants such as aspirin, thrombolytic agents such as plasminogen activators or streptokinase to achieve synergistic effects in the treatment of various
10 vascular pathologies, or lipid lowering agents including antihypercholesterolemics (e.g. HMG CoA reductase inhibitors such as lovastatin, HMG CoA synthase inhibitors, etc.) to treat or prevent atherosclerosis. For example, patients suffering from coronary artery disease, and patients subjected to angioplasty procedures, would benefit
15 from coadministration of fibrinogen receptor antagonists and thrombin inhibitors. Also, thrombin inhibitors enhance the efficiency of tissue plasminogen activator-mediated thrombolytic reperfusion. Thrombin inhibitors may be administered first following thrombus formation, and tissue plasminogen activator or other plasminogen activator is
20 administered thereafter.

Typical doses of thrombin inhibitors of the invention in combination with other suitable anti-platelet agents, anticoagulation agents, or thrombolytic agents may be the same as those doses of thrombin inhibitors administered without coadministration of
25 additional anti-platelet agents, anticoagulation agents, or thrombolytic agents, or may be substantially less than those doses of thrombin inhibitors administered without coadministration of additional anti-

platelet agents, anticoagulation agents, or thrombolytic agents, depending on a patient's therapeutic needs.

The following synthetic method can be used to prepare the compounds of the present invention. As exemplified by
 5 Example 1, the starting aminopyridine is reacted with an α -halo acetaldehyde equivalent such as bromoacetaldehyde using a base such as an acetic acid salt. The bromoacetaldehyde may be generated by acid catalysed hydrolysis from the corresponding acetal, in this case the diethyl acetal.

10



15

The following examples are illustrative of the invention as contemplated by the inventors and should not be construed as being limits on the scope or spirit of the instant invention. Starting materials are described in the identified patent publications:

20

3-(2-Phenethylamino)-6-methyl-1-(2-amino-5-methylcarboxamidomethylpyridinyl)-pyrazinone (see WO 97/40024);

3-(2-Phenethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylcarboxamidomethylpyridinyl)-pyrazinone (see WO 97/40024);

25


3-(2-Phenethylamino)-6-methyl-1-(2-amino-4-methylcarboxamidomethylpyridinyl)-pyrazinone (see WO 97/40024);

3-[2-(2-Pyridyl)ethylamino]-6-methyl-1-(2-amino-6-methyl-5-methylcarboxamidomethylpyridinyl)-pyrazinone (see WO 97/40024); and

30

3-Benzylsulfonylamino-6-methyl-1-(2-amino-6-methyl-5-methylcarboxamidomethylpyridinyl)-2-pyridinone (see WO 97/01338).


3-(2-Phenethylamino)-6-methyl-1-(2-amino-3-methyl-5-methylenecarboxamidomethylpyridinyl)-pyrazinone (I-1), used in Example 3, is prepared as follows:



- 5 EDC•HCl (115 mg, 0.60 mmol) was added to a stirred mixture of 3-(2-phenethylamino)-6-methyl-1-carboxymethylpyrazinone (144 mg, 0.50 mmol), 2-amino-5-aminomethyl-3-methylpyridine dihydrochloride (105 mg, 0.50 mmol), HOBT•H₂O (81 mg, 0.60 mmol) and N-methylmorpholine (0.275 mL, 2.5 mmol) in dry DMF (4.3 mL).
- 10 After 4 h the volatiles were evaporated *in vacuo* and the residue was suspended in dilute sodium carbonate solution and collected by filtration, washing with water, and dried to give the crude free base of the title compound. This material was purified by flash column chromatography on silica (methanol/chloroform gradient, 5-10%
- 15 methanol) to give I-1 as a white crystalline solid, m.p. >200°C; ¹H NMR (DMSO-d₆): δ 2.02 (s, 3H, CH₃), 2.04 (s, 3H, CH₃), 2.85 (t, J = 7.4 Hz, 2H, PhCH₂), 3.48 (q, J = 6.9 Hz, 2H, CH₂NH), 4.09 (d, J = 5.5 Hz, 2H, CONHCH₂), 4.58 (s, 2H, CH₂CO), 5.60 (s, 2H, NH₂), 6.64 (s, 1H, pyrazinone H-5), 6.80 (br t, J = 5.6 Hz, 1H, NH), 7.13 (s, 1H, pyridine H-4), 7.17-7.31 (m, 5H, Ph), 7.69 (s, 1H, pyridine H-6), 8.51 (br t, J = 5.6 Hz, 1H, CONH).
- 20

3-(2-Phenethylamino)-6-methyl-1-(2-amino-4-methyl-5-methylcarboxamidomethylpyridinyl)-pyrazinone bis-HCl salt (I-1a), used in Example 4, is prepared as follows:


25



3-(2-Phenethylamino)-6-methyl-1-(2-t-butoxycarbonylamino-4-methyl-5-methylcarboxamidomethylpyridinyl)-pyrazinone was prepared from 2-t-butoxycarbonylamino-5-aminomethyl-4-methylpyridine dihydrochloride using the method described for the preparation of I-1, as a colorless solid. This free base (148 mg) was dissolved in ethyl acetate (10 mL) and HCl gas was bubbled through at 0 °C for 15 min. After a further 1.5 h at rt, the volatiles were evaporated to give the title compound as a colorless solid:

¹H NMR (CD₃OD): δ 2.20 (s, 3H, CH₃), 2.42 (s, 3H, CH₃), 3.01 (t, J = 7.4 Hz, 2H, PhCH₂), 3.48 (t, J = 7.4 Hz, 2H, CH₂NH), 4.35 (d, J = 5.5 Hz, 2H, CONHCH₂), 4.77 (s, 2H, CH₂CO), 6.54 (s, 1H, pyrazinone H-5), 6.85 (s, 1H, pyridine H-3), 7.20-7.33 (m, 5H, Ph), 7.72 (s, 1H, pyridine H-6), 8.81 (br t, 1H, CONH).

3-Amino-4-cyclobutylmethylsulfonyl-6-methyl-1-(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-pyridinone (II-1), used in Example 6, is prepared as follows:



20


II-1 was prepared from bromomethylcyclobutane using the procedures for making III-6, Steps A - F, shown below.

¹H NMR (d₆ DMSO) δ 1.76-2.01 (m, 6H), 2.16 (s, 3H), 2.44 (s, 3H), 2.60 (m, 1H), 3.35 (d, J = 7.1 Hz, 2H), 4.16 (d, J = 5.1 Hz, 2H), 4.67 (s, 2H), 6.10 (br s,

25

2H), 6.15 (s, 1H), 6.80 (d, J = 9.0 Hz, 1H), 7.66 (br s, 2H), 7.76 (d, J = 9.0 Hz, 1H), 8.73 (br t, 1H).

3-Amino-4-cyclopropylmethylsulfonyl-6-methyl-1-(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone (III-6)



III-6

5

was prepared as follows:

Step A: 2-Cyclopropylmethylthiobenzothiazole (III-1)

A stirred mixture of 2-mercaptobenzothiazole (1.67 g, 10.0 mmol), bromomethylcyclopropane (0.97 mL, 10.0 mmol) and sodium hydrogencarbonate (0.84 g, 10.0 mmol) in absolute ethanol (10 ml) was heated to reflux. After 8 h, the reaction was diluted with ethyl acetate and was washed with water, sodium carbonate solution and brine, dried (Na₂SO₄) and evaporated *in vacuo* to give III-1 as an oil which was used without purification in the next step:
¹H NMR (300 Mz, CDCl₃) selected signals d 0.39 (m, 2H), 0.65 (m, 2H), 1.26 (m, 1H), 3.32 (d, J = 7.3 Hz, 2H).

Step B: 2-Cyclopropylmethylsulfonylbenzothiazole (III-2)

A solution of potassium permanganate (1.90 g, 12.0 mmol) in water (100 mL) was added to a stirred solution of 2-cyclopropylmethylthiobenzothiazole (1.90 g) in acetic acid (150 mL). After 2 h, the dark brown mixture was decolorized with 10% sodium sulfite solution and water (500 mL) was added. The resulting precipitate was collected by filtration, washing with water, and dried at 0.5 mm Hg, to give III-2 as a white crystalline solid.
¹H NMR (300 Mz, CDCl₃) selected signals d 0.28 (m, 2H), 0.64 (m, 2H), 1.21 (m, 1H), 3.46 (d, J = 7.3 Hz, 2H).

Step C: 4-Cyclopropylmethylsulfonyl-6-methyl-3-nitro-1-(ethyl-methylenecarboxy)-2-pyridinone (III-3)

Sodium borohydride (113 mg, 3.0 mmol) was added in
5 portions to a stirred mixture of 2-cyclopropylmethylsulfonyl-benzothiazole (0.38 g, 1.50 mmol) in absolute ethanol (3 mL) with cooling. After 2 h, glacial acetic acid was added dropwise to dissolve the suspension, giving a solution pH 4-5 (moist pH paper) and 4-chloro-6-methyl-3-nitro-1-(ethyl-methylenecarboxy)-2-pyridinone (275 mg, 1.0
10 mmol) was added. The solid quickly dissolves and then a thick precipitate forms. After 2 h the solids were collected by filtration, washing with ethanol, and dried at 0.5 mm Hg to give III-3 as a bright yellow powder.
¹H NMR (CDCl₃) δ 0.40 (m, 2H), 0.70 (m, 2H), 1.13 (m, 1H), 1.32 (t, J = 7.1
15 Hz, 3H), 2.46 (s, 3H), 3.33 (d, J = 7.3 Hz, 2H), 4.28 (q, J = 7.1 Hz, 2H), 4.88 (s, 2H), 6.62 (s, 1H)

Step D: 3-Amino-4-cyclopropylmethylsulfonyl-6-methyl-1-(ethyl-methylenecarboxy)-2-pyridinone (III-4)

20 A mixture of 4-cyclopropylmethylsulfonyl-6-methyl-3-nitro-1-(ethyl-methylenecarboxy)-2-pyridinone (365 mg) and 10% palladium on carbon (0.30 g) in ethyl acetate (100 mL) was stirred under an atmosphere of hydrogen (balloon) for 3 h. The reaction mixture was filtered through celite, washing with ethyl acetate, and evaporated in
25 vacuo to give III-4 as a colorless crystalline solid which was used without purification in the next step.
¹H NMR (CDCl₃) δ 0.27 (m, 2H), 0.63 (m, 2H), 1.08 (m, 1H), 1.30 (t, J = 7.1 Hz, 3H), 2.23 (d, J = 0.9 Hz, 3H), 3.02 (d, J = 7.1 Hz, 2H), 4.25 (q, J = 7.1 Hz, 2H), 4.80 (s, 2H), 5.88 (br s, 2H), 6.28 (d, J = 0.9 Hz, 1H).

30

Step E: 3-Amino-4-cyclopropylmethylsulfonyl-6-methyl-1-methylenecarboxy-2-pyridinone (III-5)

Lithium hydroxide hydrate (84 mg, 2.0 mmol) was added to a stirred mixture of 3-amino-4-cyclopropylmethylsulfonyl-6-methyl-1-
35 (ethyl-methylenecarboxy)-2-pyridinone (the product from Step D) in 2:2:1

methanol/THF/water (10 mL). After 2 h a thick white precipitate formed. The mixture was acidified with 1 M HCl to give a clear solution which was partitioned between methylene chloride and brine. The brine was re-extracted with methylene chloride and the combined organic
5 layers were dried (Na₂SO₄) and evaporated in vacuo to give a crystalline solid. This was heated to reflux as a suspension in methylene chloride (10 mL), cooled and the solids collected by filtration to give III-5 as a colorless crystalline solid.

¹H NMR (d₆ DMSO) δ 0.25 (m, 2H), 0.50 (m, 2H), 0.92 (m, 1H), 2.20 (s,
10 3H), 3.18 (d, J = 7.1 Hz, 2H), 4.73 (s, 2H), 6.16 (br s, 2H), 6.20 (s, 1H).


Step F: 3-Amino-4-cyclopropylmethylsulfonyl-6-methyl-1-(2-amino-
6-methyl-5-methylenecarboxamidomethylpyridinyl)-2-
pyridinone (III-6)

15 N-Methylmorpholine (0.187 mL, 1.70 mmol) was added to a stirred mixture of 3-amino-4-cyclopropylmethylsulfonyl-6-methyl-1-methylenecarboxy-2-pyridinone (120 mg, 0.40 mmol), 2-amino-5-aminomethyl-6-methylpyridine dihydrochloride (84 mg, 0.40 mmol), EDC.HCl (96 mg, 0.50 mmol) and HOBT.H₂O (68 mg, 0.50 mmol) in DMF
20 (2 mL). After 16 h, water (20 mL) was added to give a white precipitate and after allowing to stand for 30 min, the solids were collected by filtration, washing with water, ethanol and ethyl acetate and air dried. 9.9 M HCl in absolute ethanol (0.1 mL) was added to a stirred fine suspension of the resulting white solid in absolute ethanol (5 mL) to give
25 a solution. Over 1 h a pale yellow crystalline precipitate formed which was collected by filtration, washing with ethanol and dried at 0.5 mm Hg to give III-6 as a pale peach colored crystalline solid.

¹H NMR (d₆ DMSO) δ 0.25 (m, 2H), 0.50 (m, 2H), 0.91 (m, 1H), 2.17 (s, 3H), 2.44 (s, 3H), 3.17 (d, J = 7.1 Hz, 2H), 4.16 (d, J = 5.6 Hz, 2H), 4.68 (s, 2H), 6.12 (br s, 2H), 6.18 (d, J = 0.7 Hz, 1H), 6.80 (d, J = 9.0 Hz, 1H), 7.63
30 (br s, 2H), 7.76 (d, J = 9.0 Hz, 1H), 8.72 (br t, J = 5.6 Hz, 1H); Anal. Calc. for C₁₉H₂₅N₅O₄S.HCl.2H₂O: C 46.38, H 6.15, N 14.24. Found: C 46.51, H 6.08, N 13.89.


[R]-7-(2-amino-6-methyl-5-methylenecarboxamido-
35 methylenepyridinyl)-3-benzyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-

naphthiridin-[7H]-8-one (IV-11), used in Example 9, is prepared as follows:



5

Step A: Ethyl 6-methyl-3-nitropyridone 4-carboxylate



10

To a slurry nitroacetamide ammonia salt (70.3 g, 581 mmol) in 400 mL of deionized water was added 100 g (633 mmol, 1.09 equiv.) of ethyl 2,4-dioxovalerate followed by a solution of piperdinium acetate (prepared by adding 36 mL of piperdine to 21 mL of acetic acid in 100 mL of water). The resulting solution was stirred at 40°C for 16 h


15

then cooled in an ice bath. The precipitated product was filtered and washed with 50 mL of cold water to afford the above pyridone as a yellow solid.

¹H NMR (CDCl₃) δ 6.43 (s, 1H), 4.35 (q, J=7 Hz, 2H), 2.40 (s, 3H), 1.35 (t, J=7 Hz, 3H).


20

Step B: Ethyl 2-methoxy-6-methyl-3-nitropyridine 4-carboxylate




A solution of the pyridone from step A (6.2 g, 27.4 mmol) in 50 mL of DCM was treated with 4.47 g (30.2 mmol) of solid trimethyloxonium tetrafluoroborate and the mixture was stirred at 40°C until the reaction was judged to be complete by HPLC (typically 24-72 h). The reaction mixture was concentrated to one-third volume, loaded onto a silica gel column and eluted with 2:3 EtOAc/Hexane to afford the methoxy pyridine as a yellow liquid.
¹H NMR (CDCl₃) δ 7.2 (s, 1H), 4.35 (q, J=7 Hz, 2H), 4.05 (s, 3H), 2.55 (s, 3H), 1.35 (t, J=7 Hz, 3H).

Step C: 4-Hydroxymethyl-2-methoxy-6-methyl-3-nitropyridine



To a -70°C solution of ester from step B (5.4 g, 22.5 mmol) in 140 mL of DCM was added 56.2 mL (56.2 mmol) of DIBAL-H (1M in hexane) by dropping funnel. The resulting solution was stirred for 1h then warmed to room temperature over an additional hour. The reaction mixture was quenched by the careful addition of saturated NaK tartrate. Stirring was continued for 30 min then the solid was filtered and washed with 100 mL of DCM. The filtrate was extracted with 2 x 50 mL of saturated NaK tartrate then brine (25 mL). The yellow solution was concentrated and chromatographed (2:3 EtOAc/Hexane) to afford the desired alcohol as a yellow solid.
¹H NMR (CDCl₃) δ 7.00 (s, 1H), 4.70 (s, 2H), 4.05 (s, 3H), 2.50 (s, 3H), 2.10 (bs, 1H).


Step D: 4-Formyl-2-methoxy-6-methyl-3-nitropyridine



To a -70°C solution of oxalyl chloride (2.0 mL, 22 mmol) in 50 mL of DCM was added 3.4 mL (44 mmol) of DMSO in 10 mL of DCM by dropping funnel. After 2 min, the reaction mixture was
 5 treated with 3.99 g (20 mmol) of the alcohol from step C in 20 mL of DCM. The solution was stirred for an additional 15 min at -70°C , treated with 14 mL (50 mmol) of Et_3N and warmed to ambient temperature over 90 min. The reaction was quenched with 100 mL of water and the two
 10 phases were separated. The aqueous phase was extracted with 100 mL of DCM and the combined organic extracts were washed with 50 mL of brine and dried over MgSO_4 . The yellow solution was concentrated and chromatographed (2:3 EtOAc/Hexane) to afford the aldehyde as a yellow solid.
 15 ^1H NMR (CDCl_3) δ 10.05 (s, 1H), 7.10 (s, 1H), 4.70 (s, 2H), 4.05 (s, 3H), 2.60 (s, 3H).

Step E: Methyl-2-benzyl-3-(4-[6-methyl-2-methoxy-3-nitropyridyl])-acrylate:

20




To a 0°C solution of 2-benzyl-trimethylphosphonoacetate (1.36 g, 5.0 mmol) in 25 mL of THF was added 145 mg (4.75 mmol) of NaH. The mixture was stirred for 30 min
 25 before the dropwise addition of 930 mg (4.75 mmol) of 4-formyl-2-methoxy-3-nitropyridine in 15 mL of THF. The solution was then heated

at 50°C for 3h, cooled and evaporated. The residue was redissolved in 100 mL of EtOAc and quenched to pH=7 with saturated NH₄Cl. The organic phase was washed with brine and dried over MgSO₄. Column chromatography (2:3 EtOAc/Hexane) afforded the desired olefin as a mixture of E- and Z-isomers.

¹H NMR (CDCl₃) δ 7.60 (s, 1H), 7.40-7.00 (m, 6H), 6.60 (2 singlets, 2H), 4.00 (2 singlets, 6H), 3.75 (2 singlets, 8H), 2.40 (2 singlets, 6H).


Step F: [RS]-3-benzyl-6-methyl-8-methoxy-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridine:



To a solution of nitro olefin from step E (1.6 g, 4.75 mmol) in 50 mL of EtOAc was added 400 mg of 10% Pd(C). Hydrogen gas was added and the solution was heated at 50°C for 16. The reaction mixture was filtered through Celite and the filtrate evaporated. Column chromatography (2:3 EtOAc/Hexane) afforded the bicyclic lactam as a white solid.

¹H NMR (CDCl₃) δ 7.45 (bs, 1H), 7.40-7.20 (m, 5H), 6.45 (s, 1H), 3.95 (s, 3H), 3.35 (dd, 1H), 2.80 (m, 2H), 2.60 (m, 2H), 2.40 (s, 3H).

Step G: [RS]-3-benzyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one:




To a 23°C solution of methoxypyridine from step F (700 mg, 2.48 mmol) in 25 mL of dichloroethane was added 8.0 mL (8.0 mmol) of BBr₃ (1M in DCM). An insoluble gum precipitates within 5 min and the reaction was allowed to stir an additional 90 min before
 5 quenching to pH = 8 with saturated NaHCO₃. The mixture was diluted with 100 mL of EtOAc and 10 mL THF. The aqueous phase was discarded and the organic solution was washed with 10 mL of water then 10 mL of brine. Evaporation of the solvent left a tan colored solid which was used without further purification.

10 ¹H NMR (CDCl₃) δ 8.20 (bs, 1H), 7.40-7.10 (m, 5H), 5.88 (s, 1H), 3.35 (dd, 1H), 2.80-2.50 (m, 4H), 2.25 (s, 3H).

Step H: [RS]-3-benzyl-7-t-butoxycarbonylmethyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one:

15




(IV-8)

To a 23°C solution of pyridone from step G (630 mg, 2.5 mmol) in 20 mL of DMF was added 812 mg (2.5 mmol) of Cs₂CO₃ and
 20 0.37 mL (2.5 mmol) of tert-butyl bromoacetate. The reaction mixture was allowed to stir for 16 h before removal of the solvent *in vacuo*. The mixture was diluted with 100 mL of EtOAc and 25 mL water. The aqueous phase was discarded and the organic solution was washed with 20 mL of brine. Evaporation of the solvent and chromatography (1:1
 25 EtOAc/Hexane) of the resulting oil left the alkylated pyridone as a white solid.

¹H NMR (CDCl₃) δ 7.84 (bs, 1H), 7.33-7.17 (m, 5H), 5.87 (s, 1H), 4.79 (q, J=17.2 Hz, 2H), 3.36 (dd, J=4.1, 13.5 Hz, 1H), 2.79 (m, 1H), 2.65 (m, 2H), 2.48 (m, 1H), 2.23 (s, 3H), 1.48 (s, 9H).

30

Step I: [RS]-3-benzyl-7-carboxymethyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one:



5


To a 0°C solution of ester from step H (310 mg, 0.85 mmol) in 30 mL of DCM was added 8 mL of trifluoroacetic acid. The reaction mixture was allowed to stir to ambient temperature over 5 h before removal of the solvent *in vacuo*. The resulting solid was azeotroped with benzene, EtOAc then ether. This process yielded the desired carboxylic acid as a white solid.

¹H NMR (DMSO-d₆) δ 8.92 (bs, 1H), 7.35-7.10 (m, 5H), 6.04 (s, 1H), 4.75 (q, J=17.2 Hz, 2H), 3.16 (dd, J=4.2, 13.7 Hz, 1H), 2.79 (m, 1H), 2.65-2.40 (m, 3H), 2.1 (s, 3H).

15

Step J: [RS]-7-(2-t-butoxycarbonylamino-6-methyl-5-methylenecarboxamidomethylenepyridinyl)-3-benzyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one:

20




To a solution of acid from step I (240 mg, 0.90 mmol) and 237 mg (1.0 mmol) of 5-aminomethyl-2-boc-amino-6-methylpyridine in 5 mL of DMF was added 192 mg (1.0 mmol) of EDCI, 135 mg (1.0 mmol) of HOBT and 0.22 mL of N-methylmorpholine. The reaction mixture was allowed to stir for 16 h before removal of the solvent *in*

25

vacuo. The mixture was diluted with 20 mL of EtOAc and 5 mL water. The aqueous phase was discarded and the organic solution was washed with 3 x 5 mL of water then 10 mL of brine. Evaporation of the solvent and chromatography (9:1 EtOAc/MeOH) afforded the desired product as a white solid.

¹H NMR (CDCl₃) δ 8.47 (bs, 1H), 7.64 (d, J=9.0 Hz, 1H), 7.43-7.19 (m, 7H), 7.05 (bs, 1H), 5.95 (s, 1H), 4.75 (s, 2H), 4.37 (s, 2H), 3.32 (dd, J=4.1, 13.5 Hz, 1H), 2.79- 2.0 (m, 4H), 2.45 (s, 3H), 2.35 (s, 3H), 1.58 (s, 9H).

Step K: [R]-7-(2-amino-6-methyl-5-methylenecarboxamidomethylenepyridinyl)-3-benzyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one:




15

A solution of bicyclic substrate from step J (410 mg, 0.85 mmol) was dissolved in 12 mL of a 1:1 mixture of DCM and TFA. The reaction mixture was allowed to stir for 3 h before removal of the solvent *in vacuo*. The resulting solid was azeotroped with benzene, EtOAc then ether. This process yielded the racemate of the desired compound as a white solid. Several 3 mg samples of the free base of this compound were each dissolved in 1 mL of MeOH and the enantiomers were separated on a Chiralcel OD column (250 x 4.6 mm; A = hexane w/ 0.1% diethylamine, B = EtOH, A:B = 15/85; flow = 7 mL/min).

¹H NMR (CD₃OD) δ 7.84 (d, J=9.0 Hz, 1H), 7.40-7.20 (m, 5H), 6.79 (d, J=9.0 Hz, 1H), 6.18 (s, 1H), 4.80 (s, 2H), 4.27 (s, 2H), 3.16 (dd, J=4.1, 13.5 Hz, 1H), 2.85- 2.44 (m, 4H), 2.0 (s, 3H), 2.38 (s, 3H).


7-(2-amino-6-methyl-5-methylenecarboxamido-methylenepyridinyl)-3-[RS]-(2-[S]-methylbutyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one (V-1), used in Example 10, is prepared as follows:



The title compound was prepared by the procedure used to make [RS]-7-(2-amino-6-methyl-5-methylenecarboxamidomethylenepyridinyl)-3-benzyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one:
5 MS (FAB) 426.3 (M+1)⁺.

EXAMPLE 13-(2-Phenethylamino)-6-methyl-1-(5-methylenecarboxamidomethylene-imidazo-[1,2-a]pyridinyl)-pyrazinone dihydrochloride

5




A stirred mixture of bromoacetaldehyde diethyl acetal
 (0.76 mL, 5.1 mmol) in a solution of CHCl_3 (0.1 mL, 1.2 mmol) in water (4
 10 mL) was heated to reflux for 0.5 h. The resulting single phase solution
 was cooled, and potassium acetate (0.736 g, 7.5 mmol) was added. An
 aliquot of this solution (0.20 mL) was added to a stirred thick slurry of 3-
 (2-phenethyleneamino)-6-methyl-1-(2-amino-5-
 methylenecarboxamidomethylenepyridinyl)-pyrazinone (see WO
 15 97/40024) (46 mg, 0.10 mmol) and potassium acetate (20mg, 0.20 mmol) in
 water (0.2 mL). DMF (0.4 mL) was added to give a milky suspension.
 After 16 h the resulting mixture was acidified with sufficient 1M HCl to
 give a solution which was diluted with water (20 mL) and washed with
 methylene chloride. The aqueous layer was neutralized with saturated
 20 sodium hydrogen carbonate solution to give a thick precipitate. THF (20
 mL) was added, the aqueous layer was saturated with sodium chloride
 and the product was extracted into the organic layer, which was then
 dried (Na_2SO_4) and evaporated to give the free base of the title compound
 as a colorless solid. The free base was suspended in ethanol (2 mL) and
 25 9.9 M ethanolic HCl (4 drops) was added to give a solution which was
 evaporated *in vacuo*. Crystallization was induced in 1:1 ethanol/ethyl
 acetate and the crystalline product was heated to reflux in ethanol (1
 mL) for 1 min, cooled and collected by filtration, washing with cold
 ethanol and diethyl ether to give the title compound as a colorless
 30 powder, m.p. $>220^\circ\text{C}$:
 ^1H NMR (d_6 DMSO): δ 2.12 (s, 3H), 2.90 (t, $J = 7.6$ Hz, 2H), 3.62 (br s, 2H,
 partially obscured), 4.45 (d, $J = 5.9$ Hz, 2H), 4.69 (s, 2H), 6.69 (s, 1H), 7.19-

7.30 (m, 5H), 7.86 (d, J = 9.3 Hz, 1H), 7.98 (d, J = 9.3 Hz, 1H), 8.21 (d, J = 1.9 Hz, 1H), 8.38 (d, J = 1.9 Hz, 1H), 8.82 (s, 1H), 9.07 (br t, J = 5.9 Hz, 1 H); MS (FAB) 417 (M+1)⁺.

5

EXAMPLE 2

3-(2-Phenethyleneamino)-6-methyl-1-(4-methyl-5-methylenecarbox-
amidomethyleneimidazo[1,2-a]pyridinyl)-pyrazinone dihydrochloride



10


The title compound was prepared from 3-(2-phenethyleneamino)-6-methyl-1-(2-amino-6-methyl-5-methylenecarboxamidomethylenepyridinyl)-pyrazinone (see WO 97/40024) using the procedure of Example 1 as a colorless powder, m.p.

15

>220° C:
MS (FAB) 431 (M+1)⁺.

EXAMPLE 3

3-(2-Phenethyleneamino)-6-methyl-1-(7-methyl-5-methylenecarbox-
20 amidomethyleneimidazo[1,2-a]pyridinyl)-pyrazinone dihydrochloride




25

The title compound was prepared from 3-(2-phenethyleneamino)-6-methyl-1-(2-amino-3-methyl-5-methylenecarboxamidomethylenepyridinyl)-pyrazinone (I-1) using the procedure of Example 1, m.p. >200° C:
MS (FAB) 431 (M+1)⁺.

30

EXAMPLE 4

3-(2-Phenethylamino)-6-methyl-1-(6-methyl-5-methylenecarboxamido-methyleneimidazo[1,2-a]pyridinyl)-pyrazinone dihydrochloride



5


The title compound was prepared from 3-(2-phenethyleneamino)-6-methyl-1-(2-amino-4-methyl-5-methylenecarboxamidomethylenepyridinyl)-pyrazinone see WO 97/40024) using the procedure of Example 1, m.p. 184-186° C:

10 MS (FAB) 431 (M+1)⁺.

EXAMPLE 5

3-(2-Phenethyleneamino)-6-methyl-1-(6-methylenecarboxamidomethylene-imidazo[1,2-a]pyridinyl)-pyrazinone

15




The title compound was prepared as the free base from 3-(2-phenethyleneamino)-6-methyl-1-(2-amino-4-methylenecarboxamidomethylenepyridinyl)-pyrazinone (see WO 97/40024) using the procedure of Example 1, m.p. >200° C:

20

MS (FAB) 417 (M+1)⁺.

EXAMPLE 6


25 3-Amino-4-cyclobutylmethylenesulfonyl-6-methyl-1-(4-methyl-5-methylenecarboxamidomethyleneimidazo[1,2-a]pyridinyl)-pyridinone hydrochloride



The title compound was prepared from 3-amino-4-cyclobutylmethanesulfonyl -6-methyl-1-(2-amino-6-methyl-5-methylenecarboxamidomethylenepyridinyl)-pyridinone (II-1) using the procedure of Example 1, m.p. >200° C:
MS (FAB) 458 (M+1)⁺.

EXAMPLE 7


3-[2-(2-Pyridyl)ethyleneamino]-6-methyl-1-(4-methyl-5-methylenecarboxamidomethyleneimidazo[1,2-a]pyridinyl)-pyrazinone



The title compound was prepared as the free base from 3-[2-(2-Pyridyl)ethyleneamino]-6-methyl-1-(2-amino-6-methyl-5-methylenecarboxamidomethylenepyridinyl)-pyrazinone (see WO 97/40024) using the procedure of Example 1, m.p. >200° C:
MS (FAB) 432 (M+1)⁺.

EXAMPLE 8

3-(2-Phenethyleneamino)-6-methyl-1-(4-methyl-5-methylenecarboxamidomethyleneimidazo[1,2-a]pyridinyl)-pyrazinone hydrochloride




The title compound was prepared from 3-benzylsulfonyl-amino-6-methyl-1-(2-amino-6-methyl-5-methylenecarboxamido-methylenepyridinyl)-2-pyridinone (see WO 97/01338) using the procedure of Example 1, m.p. 175-181° C:

5 MS (FAB) 480 (M+1)⁺.

EXAMPLE 9

[R]-7-(4-methyl-5-methylenecarboxamidomethyleneimidazo[1,2-a]pyridinyl)-3-benzyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-
10 [7H]-8-one




The title compound was prepared from [R]-7-(2-amino-6-methyl-5-methylenecarboxamidomethylenepyridinyl)-3-benzyl-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one (IV-11) using the procedure of Example 1:

15 MS (FAB) 470.2 (M+1)⁺.

EXAMPLE 10

20 7-(4-methyl-5-methylenecarboxamidomethyleneimidazo[1,2-a]pyridinyl)-3-[RS]-(2-[S]-methylbutyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one



25

The title compound was prepared from 7-(2-amino-6-methyl-5-methylenecarboxamidomethylenepyridinyl)-3-[RS]-(2-[S]-

methylbutyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-1,7-naphthiridin-[7H]-8-one (V-1) using the procedure of Example 1:
MS (FAB) 450.3 (M+1)⁺.

5

EXAMPLE 11

Tablet Preparation

Tablets containing 25.0, 50.0, and 100.0 mg., respectively, of the following active compounds are prepared as illustrated below
 10 (compositions A-I). Active I is 3-Amino-4-cyclobutylmethylene-sulfonyl-6-methyl-1-(4-methyl-5-methylenecarboxamido-methyleneimidazo[1,2-a]pyridinyl)-pyrazinone hydrochloride; Active II is 3-[2-(2-Pyridyl)ethyleneamino]-6-methyl-1-(4-methyl-5-methylenecarboxamidomethyleneimidazo[1,2-a]pyridinyl)-pyrazinone;
 15 Active III is 3-(2-Phenethyleneamino)-6-methyl-1-(4-methyl-5-methylenecarboxamidomethyleneimidazo[1,2-a]pyridinyl)-pyrazinone hydrochloride; and Active IV is 3-(2-Phenethyleneamino)-6-methyl-1-(4-methyl-5-methylenecarboxamidomethyleneimidazo[1,2-a]pyridinyl)-pyrazinone dihydrochloride

20

TABLE FOR DOSES CONTAINING FROM
25-100MG OF THE ACTIVE COMPOUND

25	<u>Component</u>	<u>Amount-mg</u>								
		<u>A</u>	<u>B</u>	<u>C</u>	<u>D</u>	<u>E</u>	<u>F</u>	<u>G</u>	<u>H</u>	<u>I</u>
	Active I	25	50	100	-	-	-	-	-	-
	Active II	-	-	-	-	25	50	100	-	-
30	Active III	-	-	-	-	-	-	25	50	100
	Micro-crystalline cellulose	37.25	100	200	37.25	100	200	37.25	100	200

Modified
food

corn starch 37.25 4.25 8.5 37.25 4.25 8.5 37.25 4.25 8.5

5

Magnesium

stearate 0.5 0.75 1.5 0.5 0.75 1.5 0.5 0.75 1.5

10 All of the active compound, cellulose, and a portion of the
corn starch are mixed and granulated to 10% corn starch paste. The
resulting granulation is sieved, dried and blended with the remainder of
the corn starch and the magnesium stearate. The resulting granulation
is then compressed into tablets containing 25.0, 50.0, and 100.0 mg,
respectively, of active ingredient per tablet.

15

EXAMPLE 12

Tablet Preparation

Exemplary compositions of 3-(2-Phenethyleneamino)-6-
methyl-1-(4-methyl-5-methylenecarboxamidomethyleneimidazo[1,2-
20 a]pyridinyl)-pyrazinone dihydrochloride tablets are shown below:

<u>Component</u>	<u>0.25 mg</u>	<u>2 mg</u>	<u>10 mg</u>	<u>50 mg</u>
<u>Active IV</u>	<u>0.500%</u>	<u>1.000%</u>	<u>5.000%</u>	<u>14.29%</u>
<u>mannitol</u>	<u>49.50%</u>	<u>49.25%</u>	<u>47.25%</u>	<u>42.61%</u>
<u>microcrystalline</u>	<u>49.50%</u>	<u>49.25%</u>	<u>47.25%</u>	<u>42.61%</u>
<u>cellulose</u>				
<u>magnesium stearate</u>	<u>0.500%</u>	<u>0.500%</u>	<u>0.500%</u>	<u>0.500%</u>

2, 10 and 50 mg tablets were film-coated with an aqueous
dispersion of hydroxypropyl cellulose, hydroxypropyl methylcellulose
25 and titanium dioxide, providing a nominal weight gain of 2.4%.

Tablet preparation via direct compression

Active IV, mannitol and microcrystalline cellulose were sieved through mesh screens of specified size (generally 250 to 750 μm) and combined in a suitable blender. The mixture was subsequently
5 blended (typically 15 to 30 min) until the drug was uniformly distributed in the resulting dry powder blend. Magnesium stearate was screened and added to the blender, after which a precompression tablet blend was achieved upon additional mixing (typically 2 to 10 min). The
10 precompression tablet blend was then compacted under an applied force, typically ranging from 0.5 to 2.5 metric tons, sufficient to yield tablets of suitable physical strength with acceptable disintegration times (specifications will vary with the size and potency of the compressed tablet). In the case of the 2, 10 and 50 mg potencies, the tablets were dedusted and film-coated with an aqueous dispersion of water-soluble
15 polymers and pigment.

Tablet preparation via dry granulation

Alternatively, a dry powder blend is compacted under modest forces and remilled to afford granules of specified particle size.
20 The granules are then mixed with magnesium stearate and tabletted as stated above.

EXAMPLE 1325 Intravenous Formulations

Intravenous formulations of 3-(2-Phenethylamino)-6-methyl-1-(4-methyl-5-methylenecarboxamidomethyleneimidazo[1,2-a]pyridinyl)-pyrazinone dihydrochloride were prepared according to general intravenous formulation procedures.

30

Component	Estimated range
Active IV	0.12 - 0.61 mg
D-glucuronic acid*	0.5 - 5 mg

35

Mannitol NF 50-53 mg

Water for injection q.s. 1.0 mL

- 5 1N sodium hydroxide is used to achieve a solution pH in the range of between 3.9-4.1.

Exemplary compositions A-C are as follows:

<u>10</u>	Component	A	B	C
	Active IV	0.61 mg*	0.30**	0.15***
	D-glucuronic acid*	1.94 mg	1.94 mg	1.94 mg
<u>15</u>	Mannitol NF	51.2 mg	51.2 mg	51.2 mg
	1 N Sodium Hydroxide	q.s. pH 4.0	q.s. pH 4.0	q.s. pH 4.0
	Water for injection	q.s. 1.0 mL	q.s. 1.0 mL	q.s. 1.0 mL


- 20 * 0.50 mg free base; ** 0.25 mg free base; *** 0.12 mg free base

Various other buffer acids, such as L-lactic acid, acetic acid, citric acid or any pharmaceutically acceptable acid/conjugate base with reasonable buffering capacity in the pH range acceptable for intravenous administration may be substituted for glucuronic acid.


25

WHAT IS CLAIMED IS:

1. A compound having the formula:



5



or a pharmaceutically acceptable salt thereof, wherein




Y^1 and Y^2 are independently selected from the group consisting of

10


hydrogen,
C₁₋₄ alkyl,
C₁₋₄ alkoxy,
C₃₋₇ cycloalkyl,
15 halogen, and
trifluoromethyl;

15

A is



, or




W is -

- 5 hydrogen,
 R¹,
 R¹OCO,
 R¹CO,
 R¹SO₂,
10 R¹(CH₂)_nNHCO, or
 (R¹)₂CH(CH₂)_nNHCO,

wherein n is 0-4;

R¹ is

5 R²,
R²(CH₂)_mC(R¹²)₂, where m is 0-3, and each R¹² can be the same
or different,
(R²)(OR²)CH(CH₂)_p, where p is 1-4,



10 R²C(R¹²)₂(CH₂)_m, wherein m is 0-3, and each R¹² can be the
same or different, wherein (R¹²)₂ can also form a ring with
C represented by C3-7 cycloalkyl,

R²CH₂C(R¹²)₂(CH₂)_q, wherein q is 0-2, and each R¹² can be the
same or different, wherein (R¹²)₂ can also form a ring with
15 C represented by C3-7 cycloalkyl,

(R²)₂CH(CH₂)_r, where r is 0-4 and each R² can be the same or
different, and wherein (R²)₂ can also form a ring with CH
represented by C3-7 cycloalkyl, C7-12 bicyclic alkyl, C10-16
tricyclic alkyl, or a 5- to 7- membered mono- or bicyclic
20 heterocyclic ring which can be saturated or unsaturated,
and which contains from one to three heteroatoms selected
from the group consisting of N, O and S,

R²O(CH₂)_p, wherein p is 1-4,
R²CF₂C(R¹²)₂,
25 - (R²CH₂)(R²CH₂)CH, or
R²(COOR⁶)(CH₂)_r, where r is 1-4;




R² and R⁵ are independently
phenyl, unsubstituted or substituted with one or more of C₁₋₄
30 alkyl, C₁₋₄ alkoxy, halogen, hydroxy, COOH, CONH₂,
CH₂OH, CO₂R⁷, where R⁷ is C₁₋₄ alkyl, or SO₂NH₂,
naphthyl,

- biphenyl,
a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
heterocyclic ring or non-heterocyclic ring which can be
saturated or unsaturated, wherein the heterocyclic ring
contains from one to four heteroatoms selected from the group
consisting of N, O and S, and wherein the heterocyclic or non-
heterocyclic ring is unsubstituted or substituted with halogen or
hydroxy,
C₁₋₇ alkyl, unsubstituted or substituted with one or more of
hydroxy,
COOH,
amino,
aryl,
C₃₋₇ cycloalkyl,
CF₃,
N(CH₃)₂,
-C₁₋₃alkylaryl,
heteroaryl, or
heterocycloalkyl,
CF₃
C₃₋₇ cycloalkyl, unsubstituted or substituted with aryl,
C₇₋₁₂ bicyclic alkyl, or
C₁₀₋₁₆ tricyclic alkyl;
R³, R⁴ and R⁶ are independently selected from the group consisting of
hydrogen,
C₁₋₄ alkyl,
C₃₋₇ cycloalkyl, or
trifluoromethyl;
X is
hydrogen, or
halogen;
Z is CH₂, S, or SO₂;

R¹² is




- hydrogen,
phenyl, unsubstituted or substituted with one or more of C₁₋₄
5 alkyl, C₁₋₄ alkoxy, halogen, hydroxy, COOH, CONH₂,
naphthyl,
biphenyl,
a 5- to 7- membered mono- or a 9- to 10-membered bicyclic
heterocyclic ring which can be saturated or unsaturated, and
10 which contains from one to four heteroatoms selected from the
group consisting of N, O and S,
C₁₋₄ alkyl, unsubstituted or substituted with one or more of
hydroxy,
COOH,
15 amino,
aryl,
heteroaryl, or
heterocycloalkyl,
CF₃
20 C₃₋₇ cycloalkyl,
C₇₋₁₂ bicyclic alkyl, or
C₁₀₋₁₆ tricyclic alkyl.

2. A compound of Claim 1, or a pharmaceutically
25 acceptable salt thereof, wherein A is



3. A compound of Claim 2, or a pharmaceutically acceptable salt thereof, wherein Y^1 and Y^2 are hydrogen or C_{1-4} alkyl;
 5 W is hydrogen or R^1 ; R^1 is R^2 or R^2SO_2 ; R^2 and R^5 are independently selected from the group consisting of C_{1-7} alkyl unsubstituted or substituted with aryl, C_{3-7} cycloalkyl, or heteroaryl; R^3 and R^4 are
 10 independently selected from the group consisting of hydrogen and C_{1-4} alkyl; and Z is SO_2 .

4. A compound of Claim 3, or a pharmaceutically acceptable salt thereof, wherein Y^1 and Y^2 are hydrogen or methyl; W is
 15 hydrogen or



R⁵ is












; and

5


R³ and R⁴ are independently selected from the group consisting of hydrogen and methyl.

5. A compound of Claim 4, or a pharmaceutically
10 acceptable salt thereof, selected from the group consisting of





and



5

6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1.

10

7. A method for inhibiting thrombus formation in blood comprising adding to the blood a composition of Claim 6.

8. The use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting thrombin, inhibiting thrombus formation, treating thrombus formation, or preventing thrombus formation in a mammal.

15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/11463

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07D 471/04, 239/42 ; A61K 31/505, 31/435

US CL :546/121; 544/405; 514/253, 300

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 546/121; 544/405; 514/253, 300

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN EXPRESS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	US 5,866,573 A (SANDERSON et al.) 02 February 1999, whole document.	1-8

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

29 JULY 1999

Date of mailing of the international search report

09 SEP 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JANE FAN

Telephone No. (703) 308-0196